Chemical composition, antioxidant potential, macromolecule damage and neuroprotective activity of Convolvulus pluricaulis
2.2.2 Trial 2 (Furosemide/Rosuvastatin) In Trial 2, furosemide 40 mg and rosuvastatin 20 mg were administered in three periods, as separate single doses on consecutive days, i.e
Think HFpEF in patients with: Unexplained dyspnea Exercise intolerance Multiple comorbidities (HTN, diabetes, obesity, AF, CKD) Elderly females (higher risk group) On average, HFpEF patients have 5+ comorbid conditions
Boost energy and metabolism while supporting weight loss efforts with vitamin-rich injections that offer a holistic approach Feeling sluggish or struggling with weight loss
Mineralocorticoid receptor antagonists with sodium-glucose co-transporter-2 inhibitors in heart failure: a meta-analysis